A decade of toxicogenomic research and its contribution to toxicological science

Toxicological Sciences

Volumn 130, Issue 2, 2012, Pages 217-228

  Chen, Minjun ^a   Zhang, Min ^a   Borlak, Jürgen ^b   Tong, Weida ^a  

^a US Food and Drug Administration   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bioinformatics; Liver; Systems toxicology; Toxicogenomics

Indexed keywords

ADVERSE DRUG REACTION; ANIMAL TESTING ALTERNATIVE; ARTICLE; DECISION MAKING; DRUG CYTOTOXICITY; DRUG DEVELOPMENT; DRUG SAFETY; DRUG SCREENING; FACTUAL DATABASE; GENE EXPRESSION; HUMAN; NONHUMAN; RISK ASSESSMENT; SYSTEMS BIOLOGY; TOXICOGENETICS; TOXICOGENOMICS;

ACCESS TO INFORMATION; ANIMALS; BIBLIOMETRICS; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; DATA MINING; DATABASES, FACTUAL; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; LIVER; RISK ASSESSMENT; TIME FACTORS; TOXICITY TESTS; TOXICOGENETICS;

EID: 84869462906     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs223     Document Type: Article

References (55)

1. Abbott, A. (2005). Animal testing: More than a cosmetic change. Nature 438, 144-146.
2. Afshari, C. A., Hamadeh, H. K., and Bushel, P. R. (2011). The evolution of bioinformatics in toxicology: Advancing toxicogenomics. Toxicol. Sci. 120(Suppl. 1), S225-S237.
3. Afshari, C. A., Nuwaysir, E. F., and Barrett, J. C. (1999). Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. Cancer Res. 59, 4759-4760.
4. Bammler, T., Beyer, R. P., Bhattacharya, S., Boorman, G. A., Boyles, A., Bradford, B. U., Bumgarner, R. E., Bushel, P. R., Chaturvedi, K., Choi, D., et al. (2005). Standardizing global gene expression analysis between laboratories and across platforms. Nat. Methods 2, 351-356.
5. Barrett, T., Suzek, T. O., Troup, D. B., Wilhite, S. E., Ngau, W. C., Ledoux, P., Rudnev, D., Lash, A. E., Fujibuchi, W., and Edgar, R. (2005). NCBI GEO: Mining millions of expression profiles-database and tools. Nucleic Acids Res. 33(Database issue), D562-D566.
6. Beyer, R. P., Fry, R. C., Lasarev, M. R., McConnachie, L. A., Meira, L. B., Palmer, V. S., Powell, C. L., Ross, P. K., Bammler, T. K., Bradford, B. U., et al. (2007). Multicenter study of acetaminophen hepatotoxicity reveals the importance of biological endpoints in genomic analyses. Toxicol. Sci. 99, 326-337.
7. Blomme, E. A., Yang, Y., and Waring, J. F. (2009). Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 186, 22-31.
8. Boess, F., Kamber, M., Romer, S., Gasser, R., Muller, D., Albertini, S., and Suter, L. (2003). Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: Possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73, 386-402.
9. Boverhof, D. R., and Zacharewski, T. R. (2006). Toxicogenomics in risk assessment: Applications and needs. Toxicol. Sci. 89, 352-360.
10. Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, C., Aach, J., Ansorge, W., Ball, C. A., Causton, H. C., et al. (2001). Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29, 365-371.
11. Brazma, A., Parkinson, H., Sarkans, U., Shojatalab, M., Vilo, J., Abeygunawardena, N., Holloway, E., Kapushesky, M., Kemmeren, P., Lara, G. G., et al. (2003). ArrayExpress-A public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 31, 68-71.
12. Burgoon, L. D., Boutros, P. C., Dere, E., and Zacharewski, T. R. (2006). dbZach: A MIAME-compliant toxicogenomic supportive relational database. Toxicol. Sci. 90, 558-568.
13. Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., and Tong, W. (2011). FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 16, 697-703.
14. Cui, Y., and Paules, R. S. (2010). Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics 11, 573-585.
15. DeRisi, J., Penland, L., Brown, P. O., Bittner, M. L., Meltzer, P. S., Ray, M., Chen, Y., Su, Y. A., and Trent, J. M. (1996). Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14, 457-460.
16. Ellinger-Ziegelbauer, H., Gmuender, H., Bandenburg, A., and Ahr, H. J. (2008). Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637, 23-39.
17. Fielden, M. R., Brennan, R., and Gollub, J. (2007). A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 99, 90-100.
18. Foster, W. R., Chen, S. J., He, A., Truong, A., Bhaskaran, V., Nelson, D. M., Dambach, D. M., Lehman-McKeeman, L. D., and Car, B. D. (2007). A retrospective analysis of toxicogenomics in the safety assessment of drug candidates. Toxicol. Pathol. 35, 621-635.
19. Ganter, B., Tugendreich, S., Pearson, C. I., Ayanoglu, E., Baumhueter, S., Bostian, K. A., Brady, L., Browne, L. J., Calvin, J. T., Day, G. J., et al. (2005). Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J. Biotechnol. 119, 219-244.
20. Gerecke, D. R., Chen, M., Isukapalli, S. S., Gordon, M. K., Chang, Y. C., Tong, W., Androulakis, I. P., and Georgopoulos, P. G. (2009). Differential gene expression profiling of mouse skin after sulfur mustard exposure: Extended time response and inhibitor effect. Toxicol. Appl. Pharmacol. 234, 156-165.
21. Goodsaid, F. M., Amur, S., Aubrecht, J., Burczynski, M. E., Carl, K., Catalano, J., Charlab, R., Close, S., Cornu-Artis, C., Essioux, L., et al. (2010). Voluntary exploratory data submissions to the US FDA and the EMA: Experience and impact. Nat. Rev. Drug Discov. 9, 435-445.
22. Hamburg, M. A. (2011). Advancing regulatory science. Science 331, 987.
23. Hayes, K. R., Vollrath, A. L., Zastrow, G. M., McMillan, B. J., Craven, M., Jovanovich, S., Rank, D. R., Penn, S., Walisser, J. A., Reddy, J. K., et al. (2005). EDGE: A centralized resource for the comparison, analysis, and distribution of toxicogenomic information. Mol. Pharmacol. 67, 1360-1368.
24. Huang, J., Shi, W., Zhang, J., Chou, J. W., Paules, R. S., Gerrish, K., Li, J., Luo, J., Wolfinger, R. D., Bao, W., et al. (2010). Genomic indicators in the blood predict drug-induced liver injury. Pharmacogenomics J. 10, 267-277.
25. Jaeschke, H. (2003). Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity? Hepatology 38, 1053-1055.
26. Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499.
27. Low, Y., Uehara, T., Minowa, Y., Yamada, H., Ohno, Y., Urushidani, T., Sedykh, A., Muratov, E., Kuz'min, V., Fourches, D., et al. (2011). Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem. Res. Toxicol. 24, 1251-1262.
28. Lühe, A., Suter, L., Ruepp, S., Singer, T., Weiser, T., and Albertini, S. (2005). Toxicogenomics in the pharmaceutical industry: Hollow promises or real benefit? Mutat. Res. 575, 102-115.
29. Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M., and Gilad, Y. (2008). RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 18, 1509-1517.
30. McBurney, R. N., Hines, W. M., Von Tungeln, L. S., Schnackenberg, L. K., Beger, R. D., Moland, C. L., Han, T., Fuscoe, J. C., Chang, C. W., Chen, J. J., et al. (2009). The liver toxicity biomarker study: Phase I design and preliminary results. Toxicol. Pathol. 37, 52-64.
31. McBurney, R. N., Hines, W. M., Von Tungeln, L. S., Schnackenberg, L. K., Beger, R. D., Moland, C. L., Han, T., Fuscoe, J. C., Chang, C. W., Chen, J. J., et al. (2012). The liver toxicity biomarker study phase I: Markers for the effects of tolcapone or entacapone. Toxicol. Pathol, doi: 10.1177/0192623312444026.
32. Nagalakshmi, U., Wang, Z., Waern, K., Shou, C., Raha, D., Gerstein, M., and Snyder, M. (2008). The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 320, 1344-1349.
33. Nuwaysir, E. F., Bittner, M., Trent, J., Barrett, J. C., and Afshari, C. A. (1999). Microarrays and toxicology: The advent of toxicogenomics. Mol. Carcinog. 24, 153-159.
34. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67.
35. Roth, A., Boess, F., Landes, C., Steiner, G., Freichel, C., Plancher, J. M., Raab, S., de Vera Mudry, C., Weiser, T., and Suter, L. (2011). Gene expression-based in vivo and in vitro prediction of liver toxicity allows compound selection at an early stage of drug development. J. Biochem. Mol. Toxicol. 25, 183-194.
36. Ruepp, S., Boess, F., Suter, L., de Vera, M. C., Steiner, G., Steele, T., Weiser, T., and Albertini, S. (2005). Assessment of hepatotoxic liabilities by transcript profiling. Toxicol. Appl. Pharmacol. 207(Suppl. 2), 161-170.
37. Schena, M., Shalon, D., Davis, R. W., and Brown, P. O. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470.
38. Shi, L., Campbell, G., Jones, W. D., Campagne, F., Wen, Z., Walker, S. J., Su, Z., Chu, T. M., Goodsaid, F. M., Pusztai, L., et al. (2010b). The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol. 28, 827-838.
39. Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., Kawasaki, E. S., Lee, K. Y., et al. (2006). The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161.
40. Shi, Q., Hong, H., Senior, J., and Tong, W. (2010a). Biomarkers for drug-induced liver injury. Expert Rev. Gastroenterol. Hepatol. 4, 225-234.
41. Suter, L., Babiss, L. E., and Wheeldon, E. B. (2004). Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 11, 161-171.
42. Suter, L., Haiker, M., De Vera, M. C., and Albertini, S. (2003). Effect of two 5-HT6 receptor antagonists on the rat liver: A molecular approach. Pharmacogenomics J. 3, 320-334.
43. Suter, L., Schroeder, S., Meyer, K., Gautier, J. C., Amberg, A., Wendt, M., Gmuender, H., Mally, A., Boitier, E., Ellinger-Ziegelbauer, H., et al. (2011). EU framework 6 project: Predictive toxicology (PredTox)-Overview and outcome. Toxicol. Appl. Pharmacol. 252, 73-84.
44. Tong, W., Cao, X., Harris, S., Sun, H., Fang, H., Fuscoe, J., Harris, A., Hong, H., Xie, Q., Perkins, R., et al. (2003). ArrayTrack-supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ. Health Perspect. 111, 1819-1826.
45. Uehara, T., Minowa, Y., Morikawa, Y., Kondo, C., Maruyama, T., Kato, I., Nakatsu, N., Igarashi, Y., Ono, A., Hayashi, H., et al. (2011). Prediction model of potential hepatocarcinogenicity of rat hepatocarcinogens using a large-scale toxicogenomics database. Toxicol. Appl. Pharmacol. 255, 297-306.
46. Uehara, T., Ono, A., Maruyama, T., Kato, I., Yamada, H., Ohno, Y., and Urushidani, T. (2010). The Japanese toxicogenomics project: Application of toxicogenomics. Mol. Nutr. Food Res. 54, 218-227.
47. Ulrich, R., and Friend, S. H. (2002). Toxicogenomics and drug discovery: Will new technologies help us produce better drugs? Nat. Rev. Drug Discov. 1, 84-88.
48. Waring, J. F., Ciurlionis, R., Jolly, R. A., Heindel, M., and Ulrich, R. G. (2001). Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359-368.
49. Waters, M., Boorman, G., Bushel, P., Cunningham, M., Irwin, R., Merrick, A., Olden, K., Paules, R., Selkirk, J., Stasiewicz, S., et al. (2003). Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base. EHP Toxicogenom. 111(1T), 15-28.
50. Waters, M. D., and Fostel, J. M. (2004). Toxicogenomics and systems toxicology: Aims and prospects. Nat. Rev. Genet. 5, 936-948.
51. Wodicka, L., Dong, H., Mittmann, M., Ho, M. H., and Lockhart, D. J. (1997). Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat. Biotechnol. 15, 1359-1367.
52. Yang, Y., Abel, S. J., Ciurlionis, R., and Waring, J. F. (2006). Development of a toxicogenomics in vitro assay for the efficient characterization of compounds. Pharmacogenomics 7, 177-186.
53. Yang, Y., Blomme, E. A., and Waring, J. F. (2004). Toxicogenomics in drug discovery: From preclinical studies to clinical trials. Chem. Biol. Interact. 150, 71-85.
54. Zhang, M., Chen, M., and Tong, W. (2012). Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? Chem. Res. Toxicol. 25, 122-129.
55. Zidek, N., Hellmann, J., Kramer, P. J., and Hewitt, P. G. (2007). Acute hepatotoxicity: A predictive model based on focused illumina microarrays. Toxicol. Sci. 99, 289-302.